Latest news with #HealthTechnologyAssessment
Cision Canada
3 days ago
- Health
- Cision Canada
A joint study by Duchesnay and PeriPharm exposes critical gaps in access to innovative women's health products in Canada
The research reveals the challenges of introducing innovative medications in women's health in Canada BLAINVILLE, QC, May 29, 2025 /CNW/ - Duchesnay, member of Duchesnay Pharmaceutical Group (DPG), winner of the 2024 Life Sciences Innovation Award by ADRIQ, in collaboration with PeriPharm, is proud to announce the results of a landmark study exploring the accessibility of innovative women's health products in Canada. The research exposes systemic gaps and significant barriers that prevent Canadian women from accessing the innovative therapies they need. The study found that of the 45 women's health products approved by the U.S. Food and Drug Administration (FDA) from January 1, 2003, to December 31, 2023, only 24 (53%) had received regulatory approval by Health Canada as of July 2024 and only 13 of these products are currently reimbursed publicly. 1 "These findings highlight a clear need to address inequities in how women's health is assessed, valued and prioritized," said Dany Hallé, Vice president, Commercial Affairs, DPG. "Striving to shape women's health ecosystem in Canada, we, at Duchesnay, believe that Canadian women deserve to have timely access to healthcare innovations." Another important issue highlighted by researchers is the delays Canadian women face when it comes to approval and reimbursement processes for women's health therapies. Compared to the general access timeline for medications in Canada, the process for obtaining public coverage listing for women's health medications takes one year longer and can even exceed three years. The study suggests that the current evidence-based Health Technology Assessment (HTA) framework may not fully capture the added value of innovative drugs in women's health, potentially contributing to delays or barriers in reimbursement and market access. "This is a call to action," said Catherine Beauchemin, Ph.D., partner at PeriPharm. "This initiative marks an important first step toward improving access to innovations in women's health. To advance women's health outcomes in Canada, we must start by understanding their needs and preferences." This study will serve as a benchmark and lay the groundwork for the development of a position paper co-written by leading experts in the domain addressing the challenges women ultimately face in the assessment of innovative medicines in Canada. This white paper would be hopefully available by year end. 1 In comparison, based on data between 2016 and 2020, 67% of all new active substance approval by FDA and/or EMA have been submitted to Health Canada. ABOUT PERIPHARM Founded in 2003, PeriPharm is a Canadian company specializing in pharmacoeconomics and outcomes research. The company's mission is to provide high-quality, diversified services to ensure optimal market access of health care innovations. PeriPharm's activity is built on the belief the best available therapies should be accessible to those who need it. As a leader in the field of health economics and data generation, PeriPharm has contributed to the success of several market access initiatives. For more information about PeriPharm, please visit Follow us on LinkedIn. ABOUT DUCHESNAY Duchesnay is a specialty pharmaceutical company with a long-standing commitment to women's health. Until recently, the company focused on filling the void in terms of scientific research and education and on developing pharmacological solutions that are safe and effective for use during pregnancy and breastfeeding. Today, Duchesnay has broadened its portfolio of products to offer safe and effective therapeutic options that meet the health and quality of life needs of women and their family members at different stages of their lives. Believing that women around the world deserve to have access to specialized treatments for their conditions, Duchesnay now distributes its products internationally. For more information about Duchesnay, please visit Follow us on LinkedIn. ABOUT DUCHESNAY PHARMACEUTICAL GROUP Duchesnay Pharmaceutical Group (DPG), with its affiliated companies, is headquartered in Blainville, Quebec. The Group consists of six pharmaceutical companies to meet the needs of patients in Canada, the U.S. and abroad. The companies are Duchesnay (Canada) and Duchesnay USA, both dedicated to women's health; Medunik Canada and Medunik USA, which provide treatments for rare and debilitating diseases; and Analog Pharma Canada and Analog Pharma, specializing in orphan generic medications. From its state-of-the-art manufacturing plant, DPG exports its innovative treatments to more than 50 countries. DPG is one of the eight companies across the country chosen to participate in the Government of Canada's Global Hypergrowth Project. This appointment offers exclusive and personalized support for at least two years, in order to accelerate its growth to become an anchor firm in the Canadian economy. DPG is the winner of the 2024 Life Sciences Innovation Award by ADRIQ, the Association for the Development of Research and Innovation of Quebec, which recognizes DPG's healthy workplace culture and commitment to pharmaceutical innovation, while DPG president Éric Gervais is the recipient of the 2024 Bernard-Landry Award by ADRIQ which acknowledges his impactful leadership on Quebec's research and innovation ecosystem. DPG, through its proprietary research and development, and through exclusive partnerships, offers innovative treatments for a variety of medical conditions in women's health, urology, oncology and for rare diseases, plus lower-cost generic medications. DPG recognizes the dedication and professionalism of its employees and promotes a positive culture and flexible work environment. It is deeply committed to environmental responsibility and to giving back to the community through the support of various charitable organizations.
Associated Press
3 days ago
- Business
- Associated Press
A joint study by Duchesnay and PeriPharm exposes critical gaps in access to innovative women's health products in Canada
The research reveals the challenges of introducing innovative medications in women's health in Canada BLAINVILLE, QC, May 29, 2025 /PRNewswire/ - Duchesnay, member of Duchesnay Pharmaceutical Group (DPG), winner of the 2024 Life Sciences Innovation Award by ADRIQ, in collaboration with PeriPharm, is proud to announce the results of a landmark study exploring the accessibility of innovative women's health products in Canada. The research exposes systemic gaps and significant barriers that prevent Canadian women from accessing the innovative therapies they need. The study found that of the 45 women's health products approved by the U.S. Food and Drug Administration (FDA) from January 1, 2003, to December 31, 2023, only 24 (53%) had received regulatory approval by Health Canada as of July 2024 and only 13 of these products are currently reimbursed publicly.1 'These findings highlight a clear need to address inequities in how women's health is assessed, valued and prioritized,' said Dany Hallé, Vice president, Commercial Affairs, DPG. 'Striving to shape women's health ecosystem in Canada, we, at Duchesnay, believe that Canadian women deserve to have timely access to healthcare innovations.' Another important issue highlighted by researchers is the delays Canadian women face when it comes to approval and reimbursement processes for women's health therapies. Compared to the general access timeline for medications in Canada, the process for obtaining public coverage listing for women's health medications takes one year longer and can even exceed three years. The study suggests that the current evidence-based Health Technology Assessment (HTA) framework may not fully capture the added value of innovative drugs in women's health, potentially contributing to delays or barriers in reimbursement and market access. 'This is a call to action,' said Catherine Beauchemin, Ph.D., partner at PeriPharm. 'This initiative marks an important first step toward improving access to innovations in women's health. To advance women's health outcomes in Canada, we must start by understanding their needs and preferences.' This study will serve as a benchmark and lay the groundwork for the development of a position paper co-written by leading experts in the domain addressing the challenges women ultimately face in the assessment of innovative medicines in Canada. This white paper would be hopefully available by year end. ABOUT PERIPHARM Founded in 2003, PeriPharm is a Canadian company specializing in pharmacoeconomics and outcomes research. The company's mission is to provide high-quality, diversified services to ensure optimal market access of health care innovations. PeriPharm's activity is built on the belief the best available therapies should be accessible to those who need it. As a leader in the field of health economics and data generation, PeriPharm has contributed to the success of several market access initiatives. For more information about PeriPharm, please visit . Follow us on LinkedIn. ABOUT DUCHESNAY Duchesnay is a specialty pharmaceutical company with a long-standing commitment to women's health. Until recently, the company focused on filling the void in terms of scientific research and education and on developing pharmacological solutions that are safe and effective for use during pregnancy and breastfeeding. Today, Duchesnay has broadened its portfolio of products to offer safe and effective therapeutic options that meet the health and quality of life needs of women and their family members at different stages of their lives. Believing that women around the world deserve to have access to specialized treatments for their conditions, Duchesnay now distributes its products internationally. For more information about Duchesnay, please visit . Follow us on LinkedIn. ABOUT DUCHESNAY PHARMACEUTICAL GROUP Duchesnay Pharmaceutical Group (DPG), with its affiliated companies, is headquartered in Blainville, Quebec. The Group consists of six pharmaceutical companies to meet the needs of patients in Canada, the U.S. and abroad. The companies are Duchesnay (Canada) and Duchesnay USA, both dedicated to women's health; Medunik Canada and Medunik USA, which provide treatments for rare and debilitating diseases; and Analog Pharma Canada and Analog Pharma, specializing in orphan generic medications. From its state-of-the-art manufacturing plant, DPG exports its innovative treatments to more than 50 countries. DPG is one of the eight companies across the country chosen to participate in the Government of Canada's Global Hypergrowth Project. This appointment offers exclusive and personalized support for at least two years, in order to accelerate its growth to become an anchor firm in the Canadian economy. DPG is the winner of the 2024 Life Sciences Innovation Award by ADRIQ, the Association for the Development of Research and Innovation of Quebec, which recognizes DPG's healthy workplace culture and commitment to pharmaceutical innovation, while DPG president Éric Gervais is the recipient of the 2024 Bernard-Landry Award by ADRIQ which acknowledges his impactful leadership on Quebec's research and innovation ecosystem. DPG, through its proprietary research and development, and through exclusive partnerships, offers innovative treatments for a variety of medical conditions in women's health, urology, oncology and for rare diseases, plus lower-cost generic medications. DPG recognizes the dedication and professionalism of its employees and promotes a positive culture and flexible work environment. It is deeply committed to environmental responsibility and to giving back to the community through the support of various charitable organizations. For more information, please visit Follow us on LinkedIn. View original content to download multimedia: SOURCE Duchesnay inc.
Khaleej Times
21-04-2025
- Health
- Khaleej Times
ISPOR UAE Chapter and AbbVie announce intent to collaborate on healthcare advancement
The ISPOR UAE Chapter, the local chapter of the leading international scientific and educational organization for health economics and outcomes research (HEOR), and AbbVie, a global biopharmaceutical company, have announced their intent to explore collaborative opportunities aimed at enhancing healthcare outcomes in the UAE. The Letter of Intent (LOI) was signed during the Abu Dhabi Global Health Week in the presence of senior board members from the ISPOR UAE Chapter and senior leadership from AbbVie Gulf. The LOI signifies a mutual commitment to work together in key areas including Health Technology Assessment (HTA) and policy shaping, as well as research and evidence generation. This collaboration aims to leverage the ISPOR UAE Chapter's extensive network and knowledge in HEOR and AbbVie's scientific expertise to contribute to a more robust and evidence-based healthcare system in the UAE. Prof. Nadia Al Mazrouei, ISPOR UAE Chapter President, emphasised that 'The ISPOR UAE Chapter is dedicated to fostering excellence in health economics and outcomes research to inform healthcare decisions in the UAE. This Letter of Intent with AbbVie, formalized during the prestigious Abu Dhabi Global Health Week, marks an important step in bridging our network of researchers, policymakers, and healthcare professionals with industry expertise. We are enthusiastic about the potential of this collaboration to generate impactful research and contribute to the development of evidence-based policies that benefit patients across the UAE.' Elhussein Abdellatif, General Manager Gulf Levant AbbVie, stated, 'We are proud to reaffirm our commitment to elevating the standards of care and enhancing patients' lives. We understand the vital importance of Health Technology Assessment (HTA) and health policy in supporting access to essential therapies. Our collaboration with the ISPOR UAE Chapter provides us with an opportunity to share our expertise and collectively advance toward a more sustainable and patient-focused healthcare ecosystem in the UAE.'
Zawya
18-04-2025
- Health
- Zawya
ISPOR UAE Chapter and AbbVie announce intent to collaborate on healthcare advancement at Abu Dhabi Global Health Week
Abu Dhabi, UAE: The ISPOR UAE Chapter, the local chapter of the leading international scientific and educational organization for health economics and outcomes research (HEOR), and AbbVie, a global biopharmaceutical company, today announced their intent to explore collaborative opportunities aimed at enhancing healthcare outcomes in the UAE. The Letter of Intent (LOI) was signed during the Abu Dhabi Global Health Week in the presence of senior board members from the ISPOR UAE Chapter and senior leadership from AbbVie Gulf. The LOI signifies a mutual commitment to work together in key areas including Health Technology Assessment (HTA) and policy shaping, as well as research and evidence generation. This collaboration aims to leverage the ISPOR UAE Chapter's extensive network and knowledge in HEOR and AbbVie's scientific expertise to contribute to a more robust and evidence-based healthcare system in the UAE. Prof. Nadia Al Mazrouei, ISPOR UAE Chapter President, emphasized that 'The ISPOR UAE Chapter is dedicated to fostering excellence in health economics and outcomes research to inform healthcare decisions in the UAE. This Letter of Intent with AbbVie, formalized during the prestigious Abu Dhabi Global Health Week, marks an important step in bridging our network of researchers, policymakers, and healthcare professionals with industry expertise. We are enthusiastic about the potential of this collaboration to generate impactful research and contribute to the development of evidence-based policies that benefit patients across the UAE.' Elhussein Abdellatif, General Manager Gulf Levant AbbVie, stated, 'We are proud to reaffirm our commitment to elevating the standards of care and enhancing patients' lives. We understand the vital importance of Health Technology Assessment (HTA) and health policy in supporting access to essential therapies. Our collaboration with the ISPOR UAE Chapter provides us with an opportunity to share our expertise and collectively advance toward a more sustainable and patient-focused healthcare ecosystem in the UAE.' About ISPOR UAE Chapter: The ISPOR UAE Chapter is the local chapter of ISPOR – the International Society for Pharmacoeconomics and Outcomes Research. It serves as a platform for researchers, policymakers, healthcare professionals, and industry stakeholders in the UAE to advance the science and application of HEOR to improve healthcare decisions. About AbbVie: AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio.
